Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)-Reference-Cited by-同舟云学术

Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

Published:2011-05 Issue:10 Volume:21 Page:3152-3158
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Rosenthal Andrew S.,Tanega Cordelle,Shen Min,Mott Bryan T.,Bougie James M.,Nguyen Dac-Trung,Misteli Tom,Auld Douglas S.,Maloney David J.,Thomas Craig J.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference44 articles.

1. Regulation and Substrate Specificity of the SR Protein Kinase Clk/Sty

2. Mechanisms of Alternative Pre-Messenger RNA Splicing

3. Splicing regulation: From a parts list of regulatory elements to an integrated splicing code

4. Pre-mRNA splicing and human disease

5. A Global View of Cancer-Specific Transcript Variants by Subtractive Transcriptome-Wide Analysis

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N₁‐Benzoylated 5‐(4‐pyridinyl)indazole‐based kinase inhibitors: Attaining haspin and Clk4 selectivity via modulation of the benzoyl substituents;Archiv der Pharmazie;2024-03-13

2. Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases;Signal Transduction and Targeted Therapy;2023-04-07

3. Dual Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors: The Quest for a Disease-Modifying Treatment for Alzheimer’s Disease;Deciphering Drug Targets for Alzheimer’s Disease;2023

4. Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzheimer’s Disease;Neuromethods;2023

5. An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indications;Medicinal Research Reviews;2022-10-19